IOVA
Iovance Biotherapeutics, Inc.
6.40
USD
This page is just a preview of the data found in TrendSpider’s full version
Iovance Biotherapeutics, Inc. stock is up 61.21% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 04 Dec 14:39 | 21 Jun, 2024 | 5.00 | 1253 | ||
| 04 Dec 17:41 | 17 Jan, 2025 | 7.50 | 4371 | ||
| 04 Dec 17:43 | 21 Jun, 2024 | 10.00 | 1781 | ||
| 04 Dec 20:44 | 17 Jan, 2025 | 7.50 | 843 | ||
| 05 Dec 14:36 | 21 Jun, 2024 | 5.00 | 1353 | ||
| 05 Dec 20:42 | 15 Dec, 2023 | 5.00 | 15654 | ||
| 06 Dec 15:35 | 21 Jun, 2024 | 15.00 | 1388 | ||
| 06 Dec 20:16 | 21 Jun, 2024 | 15.00 | 1388 | ||
| 07 Dec 14:41 | 21 Jun, 2024 | 15.00 | 3070 | ||
| 08 Dec 19:27 | 15 Mar, 2024 | 9.00 | 1477 |
Iovance Biotherapeutics, Inc. focuses on developing and commercializing cancer immunotherapy products. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma. The company was incorporated in 2007 and is headquartered in San Carlos, California.
